BEYONDSPRING INC (BYSI) Stock News

USA - NASDAQ:BYSI - KYG108301006 - Common Stock

2.02 USD

-0.02 (-0.98%)

Last: 10/23/2025, 8:00:02 PM

2.02 USD

0 (0%)

Pre-Market: 10/24/2025, 9:30:00 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BYSI Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga - Mentions: MBRX CNC MOH IBIO ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: The Motley Fool

BeyondSpring Cash Jumps in Fiscal Q2

2 months ago - By: BeyondSpring, Inc.

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

4 months ago - By: BeyondSpring, Inc.

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

5 months ago - By: BeyondSpring, Inc.

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

5 months ago - By: BeyondSpring, Inc.

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: BeyondSpring, Inc.

BeyondSpring Files 2024 Annual Report on Form 10-K

7 months ago - By: BeyondSpring, Inc.

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

9 months ago - By: BeyondSpring, Inc.

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

a year ago - By: BeyondSpring, Inc.

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

a year ago - By: Benzinga - Mentions: ANGO SNGX BBLG WINT ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a year ago - By: BeyondSpring, Inc.

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

a year ago - By: BeyondSpring, Inc.

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

a year ago - By: BeyondSpring, Inc.

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

a year ago - By: BeyondSpring, Inc.

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

a year ago - By: BeyondSpring, Inc.

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

a year ago - By: BeyondSpring, Inc.

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

1 years ago - By: BeyondSpring, Inc.

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

1 years ago - By: BeyondSpring, Inc.

BeyondSpring Files 2023 Annual Report on Form 20-F

2 years ago - By: BeyondSpring, Inc.

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

2 years ago - By: InvestorPlace - Mentions: NKGN IFBD AISP MRAI ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

2 years ago - By: Seeking Alpha

BeyondSpring regains Nasdaq compliance as price surges above $1 (NASDAQ:BYSI)

2 years ago - By: Seeking Alpha

BeyondSpring gets Nasdaq delinquency notice (NASDAQ:BYSI)

2 years ago - By: BeyondSpring, Inc.

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

2 years ago - By: Seeking Alpha

BeyondSpring receives Nasdaq notice regarding minimum bid price requirements (NASDAQ:BYSI)

2 years ago - By: BeyondSpring, Inc.

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

2 years ago - By: BeyondSpring, Inc.

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium

2 years ago - By: BeyondSpring, Inc.

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

2 years ago - By: InvestorPlace - Mentions: YGMZ RDHL CFRX MREO ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

2 years ago - By: BeyondSpring, Inc.

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements